
Get Ready to Geek Out: Allogene Therapeutics Unveils Exciting Preclinical Results for ALLO-329, the Ultimate Allogeneic CD19-CD70 Dual CAR-T Therapy for Autoimmune Diseases, at ACR Conference!
Delving into Allogene Therapeutics, Inc.’s Latest Breakthrough Picture this: South San Francisco, November 18, 2024 – a stage set with excitement and anticipation as Allogene Therapeutics, Inc. unveils preclinical data for their groundbreaking ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy designed to combat autoimmune diseases. The buzz surrounding this announcement is palpable…